{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-178328","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.373025+00:00","generated_at":"2026-06-13T14:58:14.392694+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inhibikase Therapeutics announces 1-for-6 reverse stock split to regain Nasdaq compliance","bullets":["Reverse stock split effective June 30, 2023; shares outstanding reduced from ~31.6M to ~5.3M.","Stockholder approval obtained on June 23, 2023; no fractional shares issued, fractional holders get full share.","CUSIP changed to 45719W205; trading symbol remains 'IKT'.","Proportional adjustments made to stock options and warrants exercise prices and shares.","Split intended to meet Nasdaq minimum bid price requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-178328","json":"https://secwatch.observer/filing/0001193125-23-178328.json","markdown":"https://secwatch.observer/filing/0001193125-23-178328.md","text":"https://secwatch.observer/filing/0001193125-23-178328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523178328/0001193125-23-178328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523178328/d517782d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:58:14.392694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"920cb4cf4223a1aa8173b5e904187aaff69cb403","claim":"Inhibikase Therapeutics, Inc.: 1-for-6 reverse stock split via charter amendment (effective 2023-06-30).","evidence_excerpt":"On June 28, 2023, Inhibikase Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”) to effect a 1-for-6 reverse stock split (the “Reverse Stock Split”) of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), on June 30, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312523178328/0001193125-23-178328-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-06-30"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}